Metastatic Melanoma - Pipeline Review, H1 2012

Global Markets Direct, January 2012, Pages: 141

Metastatic Melanoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Metastatic Melanoma - Pipeline Review, H1 2012', provides an overview of the Metastatic Melanoma therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. 'Metastatic Melanoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Melanoma.
- A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Metastatic Melanoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Metastatic Melanoma Therapeutic Products under Development, Key Players in Metastatic Melanoma Therapeutics, Metastatic Melanoma Pipeline Overview, Metastatic Melanoma Pipeline, Metastatic Melanoma Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metastatic Melanoma Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Melanoma
Metastatic Melanoma Therapeutics under Development by Companies
Metastatic Melanoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Metastatic Melanoma Therapeutics – Products under Development by Companies
Metastatic Melanoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Melanoma Therapeutics Development
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Vical Incorporated
Adherex Technologies Inc.
Viralytics Ltd.
GlaxoSmithKline plc
Genentech, Inc.
MedImmune LLC
Emergent BioSolutions Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
ImClone Systems Incorporated
Pain Therapeutics, Inc.
Celgene Corporation
3SBio Inc.
EpiCept Corporation
Celldex Therapeutics, Inc.
Molecular Insight Pharmaceuticals, Inc.
Northwest Biotherapeutics, Inc.
Osta Biotechnologies Inc.
Advanced Life Sciences Holdings, Inc.
Progen Pharmaceuticals Limited
Threshold Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc.
BioAlliance Pharma SA
Piramal Life Sciences Limited
Morphotek, Inc.
Antisense Pharma GmbH
Philogen S.p.A.
Curacyte AG
Cytheris SA
Altor BioScience Corporation
Affichem
Myriad Pharmaceuticals, Inc.
Omeros Corporation
Immunocore Limited.
CureTech Ltd.
Medisyn Technologies, Inc.
Cytavis Biopharma GmbH
Gradalis Inc.
Lipotek Pty Ltd
Metastatic Melanoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
GSK1120212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allovectin-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zelboraf - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abraxane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NuLeusin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aldesleukin + Vaccine Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GP100 Antigen + Incomplete Freund's adjuvant + Aldesleukin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aldesleukin + Ceplene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDX-010 + DTIC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aldesleukin + Gp100 Antigen + Incomplete Freund's Adjuvant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MART-1 Antigen + GP-100 Antigen + Tyrosinase Peptide + GM-CSF + Incomplete Freund's Adjuvant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2118436 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interleukin-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Melanoma Therapeutics – Drug Profile Updates
Metastatic Melanoma Therapeutics – Discontinued Products
Metastatic Melanoma Therapeutics - Dormant Products
Metastatic Melanoma – Product Development Milestones
Featured News & Press Releases
Dec 16, 2011: Roche's Zelboraf Receives Positive Opinion From European Authority For Treatment Of People With BRAF Mutation-Positive Metastatic Melanoma
Nov 29, 2011: Provectus Reports On Third End-Of-Phase II Meeting With FDA To Define Pathway To Approval Of PV-10 for Metastatic Melanoma
Nov 22, 2011: Researchers Identify P Rex-1 Protein That Contributes To Development Of Melanoma
Nov 14, 2011: Provectus Presents Data On PV-10 For Metastatic Melanoma At 2011 International Melanoma Congress
Nov 10, 2011: Phase II Data on Provectus’s PV-10 For Metastatic Melanoma To Be Presented At 2011 International Melanoma Congress
Sep 13, 2011: BioAlliance Announces Positive Preliminary Phase I Clinical Results With AMEP Biotherapy For Metastatic Melanoma
Aug 17, 2011: Roche Announces FDA Approval For Zelboraf And Companion Diagnostic For BRAF Mutation-Positive Metastatic Melanoma
Aug 02, 2011: Jennerex Reports Positive Mechanistic Proof Of Concept Clinical Trial Results Using JX-594 To Treat Metastatic Melanoma
Jul 13, 2011: CYTAVIS's Aviscumine Improves Survival Of Patients With Metastatic Melanoma In Phase II Trial
Jun 29, 2011: Provectus Presents Additional Data On PV-10 For Metastatic Melanoma At Prominent Melanoma Conferences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Metastatic Melanoma, H1 2012
Products under Development for Metastatic Melanoma – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Bristol-Myers Squibb Company, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Abbott Laboratories, H1 2012
Vical Incorporated, H1 2012
Adherex Technologies Inc., H1 2012
Viralytics Ltd., H1 2012
GlaxoSmithKline plc, H1 2012
Genentech, Inc., H1 2012
MedImmune LLC, H1 2012
Emergent BioSolutions Inc., H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
Novartis AG, H1 2012
ImClone Systems Incorporated, H1 2012
Pain Therapeutics, Inc., H1 2012
Celgene Corporation, H1 2012
3SBio Inc., H1 2012
EpiCept Corporation, H1 2012
Celldex Therapeutics, Inc., H1 2012
Molecular Insight Pharmaceuticals, Inc., H1 2012
Northwest Biotherapeutics, Inc., H1 2012
Osta Biotechnologies Inc., H1 2012
Advanced Life Sciences Holdings, Inc., H1 2012
Progen Pharmaceuticals Limited, H1 2012
Threshold Pharmaceuticals, Inc., H1 2012
Provectus Pharmaceuticals, Inc., H1 2012
BioAlliance Pharma SA, H1 2012
Piramal Life Sciences Limited, H1 2012
Morphotek, Inc., H1 2012
Antisense Pharma GmbH, H1 2012
Philogen S.p.A., H1 2012
Curacyte AG, H1 2012
Cytheris SA, H1 2012
Altor BioScience Corporation, H1 2012
Affichem, H1 2012
Myriad Pharmaceuticals, Inc., H1 2012
Omeros Corporation, H1 2012
Immunocore Limited., H1 2012
CureTech Ltd., H1 2012
Medisyn Technologies, Inc., H1 2012
Cytavis Biopharma GmbH, H1 2012
Gradalis Inc., H1 2012
Lipotek Pty Ltd, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Metastatic Melanoma Therapeutics – Drug Profile Updates
Metastatic Melanoma Therapeutics – Discontinued Products
Metastatic Melanoma Therapeutics – Discontinued Products (Contd..1)
Metastatic Melanoma Therapeutics – Dormant Products
Metastatic Melanoma Therapeutics – Dormant Products (Contd..1)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..2)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..3)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..4)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..5)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..6)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..7)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..8)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..9)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..10)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..11)
Metastatic Melanoma Therapeutics – Dormant Products (Contd..12)

List of Figures
Number of Products under Development for Metastatic Melanoma, H1 2012
Products under Development for Metastatic Melanoma – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• HIV / AIDS – Pipeline Review, H1 2013
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Rheumatoid Arthritis - Pipeline Review, H1 2013
• Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2013
• Melanoma - Pipeline Review, H2 2012
• Hepatitis - Pipeline Review, H1 2013
• Neuropathic Pain - Pipeline Review, H1 2013
• Metastatic Colorectal Cancer - Pipeline Review, H2 2012
• Eczema - Pipeline Review, H1 2013